公开(公告)号：WO2018045250A1

公开(公告)日：2018-03-08

申请号：PCT/US2017/049778

申请日：2017-08-31

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： DAWSON, Ted M. ,  DAWSON, Valina L. ,  WANG, Yingfei ,  PARK, Hyejin ,  LIU, Jun ,  PENG, Hanjing

IPC: A61P25/00 ,  A61P25/28 ,  A61K38/17

Abstract: Provided herein are methods of treating a disease, such as Parkinson's disease, that is due to increased poly [ADP-ribose] polymerase 1 (PARP-1) activation, by inhibiting macrophage migration inhibitory factor (MIF) nuclease activity.

Abstract translation: 本文提供了治疗由于增加的聚[ADP-核糖]聚合酶1（PARP-1）激活，通过抑制巨噬细胞迁移抑制因子（MIF）引起的疾病（例如帕金森氏病）的方法 ）核酸酶活性。

公开(公告)号：WO2020047414A1

公开(公告)日：2020-03-05

申请号：PCT/US2019/049071

申请日：2019-08-30

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： LEE, Seulki ,  KO, Han Seok ,  DAWSON, Ted M. ,  POMPER, Martin G. ,  KIM, Donghoon ,  OH, Yumin ,  KWON, Seung-Hwan ,  PARK, Yong Joo

IPC: A61K38/17 ,  A61K45/00 ,  A61P25/00

Abstract: Provided herein are compositions comprising a RIPK2 inhibitor and methods of using the RIPK2 inhibitor for treating or preventing neurodegenerative diseases or disorders. Also provided herein are methods of screening or identifying therapeutic agents useful for treating or preventing neurodegenerative diseases or disorders.

公开(公告)号：WO2015157514A1

公开(公告)日：2015-10-15

申请号：PCT/US2015/025103

申请日：2015-04-09

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： DAWSON, Ted M. ,  DAWSON, Valina ,  LEE, Byoung-Dae ,  MARTIN, Ian

IPC: G01N33/573 ,  C12Q1/48 ,  C12Q1/68 ,  A61K39/395 ,  A61P25/16 ,  C07K16/40

CPC classification number: C07K16/40 ,  C07K16/18 ,  C07K16/44 ,  C07K2317/34 ,  C12Q1/485 ,  G01N2333/9121

Abstract: The present invention relates to the field of neurodegenerative diseases. More specifically, the present invention provides methods and compositions useful for treating Parkinson's disease. In a specific embodiment, a method for reducing Parkinson's Disease-related neurotoxicity in a patient comprising the step of administering to the patient an effective amount of an agent that inhibits the phosphorylation of RPS15 by LRRK2.

Abstract translation: 本发明涉及神经变性疾病领域。 更具体地，本发明提供了可用于治疗帕金森病的方法和组合物。 在一个具体实施方案中，一种用于降低患者中帕金森病相关神经毒性的方法，包括向患者施用有效量的抑制LRRK2磷酸化RPS15的药剂的步骤。

公开(公告)号：WO2018039147A1

公开(公告)日：2018-03-01

申请号：PCT/US2017/047878

申请日：2017-08-22

Applicant: THE JOHNS HOPKINS UNIVERSITY ,  UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Inventor： DAWSON, Ted M. ,  DAWSON, Valina L. ,  KO, Han Seok ,  MAO, Xiaobo ,  ALBERTO VIGNALI, Dario Angelo ,  WORKMAN, Creg J.

IPC: A61K38/00 ,  A61K48/00 ,  A61P25/16 ,  A61P25/28

CPC classification number: C07K16/2803 ,  A01K2217/052 ,  A01K2227/105 ,  A01K2267/0318 ,  A61K31/713 ,  A61P21/00 ,  A61P25/16 ,  A61P25/28 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/11 ,  G01N33/573 ,  G01N33/6896 ,  G01N2500/02 ,  G01N2800/2835

Abstract: Described are methods of inhibiting neurodegeneration in a subject by administering to the subject an agent that prevents (alpha)-syn PFF from binding to its receptor. The agent may be a small molecule chemical compound, antibody, nucleic acid molecule, or polypeptide. Drug screening methods are also provided.

Abstract translation: 描述了抑制受试者神经变性的方法，其通过向受试者施用防止α-syn PFF与其受体结合的试剂。 试剂可以是小分子化合物，抗体，核酸分子或多肽。 还提供了药物筛选方法。

公开(公告)号：WO2011057204A2

公开(公告)日：2011-05-12

申请号：PCT/US2010/055857

申请日：2010-11-08

Applicant: THE JOHNS HOPKINS UNIVERSITY ,  LEE, Byoung Dae ,  DAWSON, Ted M. ,  DAWSON, Valina L. ,  WEST, Andrew B.

Inventor： LEE, Byoung Dae ,  DAWSON, Ted M. ,  DAWSON, Valina L. ,  WEST, Andrew B.

IPC: A61K31/403 ,  A61K31/416 ,  A61K31/404 ,  A61K31/519 ,  A61P25/28 ,  A61P25/00

CPC classification number: A61K31/553 ,  A61K31/122 ,  A61K31/403 ,  A61K31/404 ,  A61K31/416 ,  A61K31/519 ,  A61K31/7064

Abstract: Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration were identified. The presently disclosed subject matter establishes that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for treating Parkinson's disease.

Abstract translation: 亮氨酸重复激酶-2（LRRK2）突变是帕金森病的常见病因。 鉴定了在LRRK2诱导的神经变性的体外和体内模型中保护的LRRK2激酶的抑制剂。 目前公开的主题确定LRRK2诱导的体内神经元的变性是激酶依赖性的，并且LRRK2激酶抑制提供了治疗帕金森病的潜在的新的神经保护范例。